{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:56:20Z","timestamp":1783626980081,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["No. 2020M3A9I2108860"],"award-info":[{"award-number":["No. 2020M3A9I2108860"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["No. 2022M3A9J1072296"],"award-info":[{"award-number":["No. 2022M3A9J1072296"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00204-023-03446-y","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:16:44Z","timestamp":1674447404000},"page":"1177-1189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical safety assessment of the suction-assisted intradermal injection of the SARS-CoV-2 DNA vaccine candidate pGO-1002 in white rabbit"],"prefix":"10.1007","volume":"97","author":[{"given":"Seunghee","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Seong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Jin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Seok","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyojin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areum","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohyun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel N.","family":"Maslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Bum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-6837","authenticated-orcid":false,"given":"Kang-Hyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"issue":"9","key":"3446_CR1","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/infdis\/jix456","volume":"216","author":"JA Ake","year":"2017","unstructured":"Ake JA, Schuetz A, Pegu P et al (2017) Safety and immunogenicity of PENNVAX-G DNA prime administered by Biojector 2000 or CELLECTRA electroporation device with modified vaccinia Ankara-CMDR boost. J Infect Dis 216(9):1080\u20131090. https:\/\/doi.org\/10.1093\/infdis\/jix456","journal-title":"J Infect Dis"},{"issue":"24","key":"3446_CR2","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1001\/jama.2020.6641","volume":"323","author":"TJ Bollyky","year":"2020","unstructured":"Bollyky TJ, Gostin LO, Hamburg MA (2020) The equitable distribution of COVID-19 therapeutics and vaccines. JAMA 323(24):2462\u20132463. https:\/\/doi.org\/10.1001\/jama.2020.6641","journal-title":"JAMA"},{"issue":"13","key":"3446_CR3","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jama.2021.3199","volume":"325","author":"CB Creech","year":"2021","unstructured":"Creech CB, Walker SC, Samuels RJ (2021) SARS-CoV-2 vaccines. JAMA 325(13):1318\u20131320. https:\/\/doi.org\/10.1001\/jama.2021.3199","journal-title":"JAMA"},{"key":"3446_CR4","unstructured":"FDA US (2020) 21CFR58 Good laboratory practice for nonclinical laboratory studies. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=58"},{"issue":"10120","key":"3446_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","volume":"391","author":"MR Gaudinski","year":"2018","unstructured":"Gaudinski MR, Houser KV, Morabito KM et al (2018) Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391(10120):552\u2013562. https:\/\/doi.org\/10.1016\/S0140-6736(17)33105-7","journal-title":"Lancet"},{"issue":"3","key":"3446_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/vaccines8030377","volume":"8","author":"J Hooper","year":"2020","unstructured":"Hooper J, Paolino KM, Mills K et al (2020) A phase 2a randomized, double-blind, dose-optimizing study to evaluate the immunogenicity and safety of a bivalent DNA vaccine for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Vaccines 8(3):377. https:\/\/doi.org\/10.3390\/vaccines8030377","journal-title":"Vaccines"},{"key":"3446_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fviro.2022.891540","author":"M Jeong","year":"2022","unstructured":"Jeong M, Kudchodkar SB, Gil A et al (2022) Immune responses of a novel bi-cistronic SARS-CoV-2 DNA vaccine following intradermal immunization with suction delivery. Front Virol. https:\/\/doi.org\/10.3389\/fviro.2022.891540","journal-title":"Front Virol"},{"issue":"10332","key":"3446_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","volume":"399","author":"A Khobragade","year":"2022","unstructured":"Khobragade A, Bhate S, Ramaiah V et al (2022) Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. The Lancet 399(10332):1313\u20131321. https:\/\/doi.org\/10.1016\/S0140-6736(22)00151-9","journal-title":"The Lancet"},{"issue":"45","key":"3446_CR9","doi-asserted-by":"publisher","first-page":"eabj0611","DOI":"10.1126\/sciadv.abj0611","volume":"7","author":"EO Lallow","year":"2021","unstructured":"Lallow EO, Jhumur NC, Ahmed I et al (2021) Novel suction-based in vivo cutaneous DNA transfection platform. Sci Adv 7(45):eabj0611. https:\/\/doi.org\/10.1126\/sciadv.abj0611","journal-title":"Sci Adv"},{"key":"3446_CR11","unstructured":"MFDS (2014) Guideline On Nonclinical Evaluation of Biopharmaceuticals. https:\/\/www.mfds.go.kr\/brd\/m_1060\/view.do?seq=12959&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=76"},{"key":"3446_CR12","unstructured":"MFDS (2017) Notice No. 2017\u201371. Standard for Toxicity Study of Pharmaceuticals. https:\/\/www.mfds.go.kr\/eng\/brd\/m_18\/view.do?seq=71459&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1"},{"key":"3446_CR10","first-page":"NA","volume":"NA","author":"MFDS","year":"2018","unstructured":"MFDS (2018)  Notification No. 2018-93. Good Laboratory Practice.\u00a0https:\/\/www.mfds.go.kr\/eng\/brd\/m_18\/view.do?seq=71480&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=3","journal-title":"NA"},{"issue":"9","key":"3446_CR13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad K, Roberts CC, Mills KT et al (2019) Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 19(9):1013\u20131022. https:\/\/doi.org\/10.1016\/S1473-3099(19)30266-X","journal-title":"Lancet Infect Dis"},{"key":"3446_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101020","volume":"38","author":"T Momin","year":"2021","unstructured":"Momin T, Kansagra K, Patel H et al (2021) Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine 38:101020. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101020","journal-title":"EClinicalMedicine"},{"key":"3446_CR15","unstructured":"OECD (1998) OECD Principles on Good Laboratory Practice. ENV\/MC\/CHEM(98)17. https:\/\/read.oecd-ilibrary.org\/environment\/oecd-principles-on-good-laboratory-practice_9789264078536-en#page1"},{"issue":"4","key":"3446_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov 17(4):261\u2013279. https:\/\/doi.org\/10.1038\/nrd.2017.243","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3446_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/hgtb.2017.105","volume":"29","author":"K Schultheis","year":"2018","unstructured":"Schultheis K, Smith TRF, Kiosses WB et al (2018) Delineating the cellular mechanisms associated with skin electroporation. Hum Gene Ther Methods 29(4):177\u2013188. https:\/\/doi.org\/10.1089\/hgtb.2017.105","journal-title":"Hum Gene Ther Methods"},{"issue":"5","key":"3446_CR18","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.1016\/S2214-109X(21)00043-7","volume":"9","author":"M Shrotri","year":"2021","unstructured":"Shrotri M, Swinnen T, Kampmann B, Parker EPK (2021) An interactive website tracking COVID-19 vaccine development. Lancet Glob Health 9(5):e590\u2013e592. https:\/\/doi.org\/10.1016\/S2214-109X(21)00043-7","journal-title":"Lancet Glob Health"},{"issue":"1","key":"3446_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/14712598.2017.1248941","volume":"17","author":"I Slivac","year":"2017","unstructured":"Slivac I, Guay D, Mangion M, Champeil J, Gaillet B (2017) Non-viral nucleic acid delivery methods. Expert Opin Biol Ther 17(1):105\u2013118. https:\/\/doi.org\/10.1080\/14712598.2017.1248941","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"3446_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708120","volume":"385","author":"P Tebas","year":"2021","unstructured":"Tebas P, Roberts CC, Muthumani K et al (2021) Safety and immunogenicity of an anti\u2013Zika virus DNA vaccine. N Engl J Med 385(12):e35. https:\/\/doi.org\/10.1056\/NEJMoa1708120","journal-title":"N Engl J Med"},{"issue":"8","key":"3446_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","volume":"19","author":"D van Riel","year":"2020","unstructured":"van Riel D, de Wit E (2020) Next-generation vaccine platforms for COVID-19. Nat Mater 19(8):810\u2013812. https:\/\/doi.org\/10.1038\/s41563-020-0746-0","journal-title":"Nat Mater"},{"issue":"5","key":"3446_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/mt.2009.27","volume":"17","author":"M Wallace","year":"2009","unstructured":"Wallace M, Evans B, Woods S et al (2009) Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Mol Ther 17(5):922\u2013928. https:\/\/doi.org\/10.1038\/mt.2009.27","journal-title":"Mol Ther"},{"key":"3446_CR23","first-page":"616","volume-title":"Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines","author":"WHO","year":"2013","unstructured":"WHO (2013) Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines. World Health Organization, Geneva, pp 616\u2013624"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-023-03446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-023-03446-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-023-03446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:46:43Z","timestamp":1679881603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-023-03446-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3446"],"URL":"https:\/\/doi.org\/10.1007\/s00204-023-03446-y","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"19 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.L., A.G., B.J., C.C.R., J.N.M are employees of GeneOne Life Science, Inc. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Association for Assessment and Accreditation of Laboratory Animal Care International. This study was approved by the Institutional Animal Care and Use Committee of the Korea Institute of Toxicology (Approval No. 2008-0240). The manuscript does not contain any clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}